Equities research analysts at UBS Group initiated coverage on shares of Amedisys (NASDAQ:AMED) in a research report issued on Thursday, Analyst Price Targets reports. The brokerage set a “sell” rating and a $150.00 price target on the health services provider’s stock. UBS Group’s price objective indicates a potential downside of 3.44% from the company’s current price.
Other equities research analysts have also recently issued reports about the stock. Raymond James cut their price target on shares of Amedisys from $325.00 to $250.00 and set an “outperform” rating on the stock in a research report on Monday, August 9th. Oppenheimer reissued a “buy” rating and set a $265.00 price target on shares of Amedisys in a research report on Friday, September 17th. Zacks Investment Research cut shares of Amedisys from a “buy” rating to a “hold” rating and set a $273.00 price target on the stock. in a research report on Tuesday, June 15th. Credit Suisse Group cut their price target on shares of Amedisys from $330.00 to $250.00 and set an “outperform” rating on the stock in a research report on Wednesday, August 11th. Finally, Cowen started coverage on shares of Amedisys in a report on Thursday, September 9th. They issued a “market perform” rating and a $195.00 target price on the stock. One research analyst has rated the stock with a sell rating, four have assigned a hold rating and seven have given a buy rating to the company’s stock. According to data from MarketBeat, Amedisys has an average rating of “Buy” and a consensus target price of $260.62.
Shares of NASDAQ AMED opened at $155.35 on Thursday. The firm has a market cap of $5.07 billion, a PE ratio of 20.85, a PEG ratio of 2.69 and a beta of 0.51. The company has a current ratio of 0.87, a quick ratio of 0.87 and a debt-to-equity ratio of 0.20. Amedisys has a 1-year low of $154.52 and a 1-year high of $325.12. The company has a fifty day moving average price of $199.46 and a 200 day moving average price of $241.19.
Amedisys declared that its Board of Directors has approved a share buyback plan on Wednesday, August 4th that authorizes the company to repurchase $100.00 million in outstanding shares. This repurchase authorization authorizes the health services provider to reacquire up to 1.2% of its stock through open market purchases. Stock repurchase plans are often an indication that the company’s board believes its shares are undervalued.
In other Amedisys news, Director Bruce D. Perkins sold 11,511 shares of the stock in a transaction that occurred on Wednesday, September 1st. The shares were sold at an average price of $183.00, for a total transaction of $2,106,513.00. Following the transaction, the director now owns 29,380 shares in the company, valued at approximately $5,376,540. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, COO Christopher Gerard sold 1,250 shares of the stock in a transaction that occurred on Monday, August 2nd. The stock was sold at an average price of $261.24, for a total transaction of $326,550.00. Following the transaction, the chief operating officer now owns 39,006 shares in the company, valued at approximately $10,189,927.44. The disclosure for this sale can be found here. 1.80% of the stock is currently owned by corporate insiders.
Several large investors have recently made changes to their positions in AMED. Thrivent Financial for Lutherans grew its position in shares of Amedisys by 4,126.1% during the 1st quarter. Thrivent Financial for Lutherans now owns 363,021 shares of the health services provider’s stock worth $96,125,000 after purchasing an additional 354,431 shares in the last quarter. Ameriprise Financial Inc. grew its position in shares of Amedisys by 49.2% during the 1st quarter. Ameriprise Financial Inc. now owns 798,307 shares of the health services provider’s stock worth $211,397,000 after purchasing an additional 263,329 shares in the last quarter. Amundi acquired a new position in shares of Amedisys during the 2nd quarter worth approximately $48,004,000. BlackRock Inc. boosted its position in shares of Amedisys by 3.0% during the 1st quarter. BlackRock Inc. now owns 4,101,173 shares of the health services provider’s stock worth $1,085,950,000 after acquiring an additional 120,989 shares in the last quarter. Finally, Morgan Stanley boosted its position in shares of Amedisys by 341.5% during the 2nd quarter. Morgan Stanley now owns 132,183 shares of the health services provider’s stock worth $32,374,000 after acquiring an additional 102,246 shares in the last quarter. Hedge funds and other institutional investors own 87.35% of the company’s stock.
Amedisys, Inc engages in the provision of healthcare services. It operates through the following business segments: Home Health, Hospice, and Personal Care. The Home Health segment delivers services in the homes of individuals who may be recovering from an illness, injury, or surgery. The Hospice segment provides care that is designed to provide comfort and support for those who are facing a terminal illness.
Further Reading: Green Investing
Receive News & Ratings for Amedisys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amedisys and related companies with MarketBeat.com's FREE daily email newsletter.